Advertisement

Antibodies as Cancer Immunotherapy

  • Devalingam Mahalingam
  • Tyler J. Curiel
Chapter

Abstract

Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of  Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.

Keywords

Epidermal Growth Factor Receptor Human Epidermal Growth Factor Receptor Chronic Lymphocytic Leukemia Metastatic Colorectal Cancer KRAS Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Thanks to our colleagues for many informative discussions. This work was supported by CA105207, CA054174, FD003118, the Fanny Rippel Foundation, the Voelcker Trust, the Hayes Endowment, The Holly Beach Public Library Association, The Owens Foundation, The Hogg Foundation and UTHSCSA endowments.

References

  1. 1.
    Gensini GF, Conti AA, Lippi D (2007) The contributions of Paul Ehrlich to infectious disease. J Infect 54:221–224PubMedCrossRefGoogle Scholar
  2. 2.
    Silverstein AM (2002) The collected papers of Paul Ehrlich: why was volume 4 never published? Bull Hist Med 76:335–339PubMedCrossRefGoogle Scholar
  3. 3.
    Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev\ 6:559–565CrossRefGoogle Scholar
  4. 4.
    Kreitman RJ, Pastan I (2006) Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 7:1301–1311PubMedCrossRefGoogle Scholar
  5. 5.
    Akhtar S, Maghfoor I (2002) Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 346:1830–1831, author reply 1830–1831PubMedCrossRefGoogle Scholar
  6. 6.
    Keating MJ et al (2002) Therapeutic role of alemtuzumab (Campath-1 H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561PubMedCrossRefGoogle Scholar
  7. 7.
    Shankaran V et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111PubMedCrossRefGoogle Scholar
  8. 8.
    Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287PubMedCrossRefGoogle Scholar
  9. 9.
    Sharma P, Wagner K, Wolchok JD, Allison JP (2012) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805–812CrossRefGoogle Scholar
  10. 10.
    Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446PubMedCrossRefGoogle Scholar
  11. 11.
    Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125–133PubMedCrossRefGoogle Scholar
  12. 12.
    Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–327PubMedCrossRefGoogle Scholar
  13. 13.
    Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune responses. Immunol Rev 236:265–275PubMedCrossRefGoogle Scholar
  14. 14.
    Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47PubMedCrossRefGoogle Scholar
  15. 15.
    Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96:179–204PubMedCrossRefGoogle Scholar
  16. 16.
    Nimmerjahn F, Ravetch JV (2007) Antibodies, Fc receptors and cancer. Curr Opin Immunol 19:239–245PubMedCrossRefGoogle Scholar
  17. 17.
    Gualberto A (2012) Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 21:205–216PubMedCrossRefGoogle Scholar
  18. 18.
    Hooks MA, Wade CS, Millikan WJ Jr (1991) Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11:26–37PubMedGoogle Scholar
  19. 19.
    Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  20. 20.
    Castillo FJ et al (1994) Hybridoma stability. Dev Biol Stand 83:55–64PubMedGoogle Scholar
  21. 21.
    Castillo FJ, Mullen LJ, Thrift JC, Grant BC (1992) Perfusion cultures of hybridoma cells for monoclonal antibody production. Ann N Y Acad Sci 665:72–80PubMedCrossRefGoogle Scholar
  22. 22.
    Ma JK et al (1998) Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 4:601–606PubMedCrossRefGoogle Scholar
  23. 23.
    Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11–23PubMedCrossRefGoogle Scholar
  24. 24.
    Hoogenboom HR, Chames P (2000) Natural and designer binding sites made by phage display technology. Immunol Today 21:371–378PubMedCrossRefGoogle Scholar
  25. 25.
    Vaughan TJ, Osbourn JK, Tempest PR (1998) Human antibodies by design. Nat Biotechnol 16:535–539PubMedCrossRefGoogle Scholar
  26. 26.
    Adair JR (1992) Engineering antibodies for therapy. Immunol Rev 130:5–40PubMedCrossRefGoogle Scholar
  27. 27.
    Morrison SL, Oi VT (1989) Genetically engineered antibody molecules. Adv Immunol 44:65–92PubMedCrossRefGoogle Scholar
  28. 28.
    Krauss J (2003) Recombinant antibodies for the diagnosis and treatment of cancer. Mol Biotechnol 25:1–17PubMedCrossRefGoogle Scholar
  29. 29.
    Peterson NC (1996) Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies. Lab Anim Sci 46:8–14PubMedGoogle Scholar
  30. 30.
    Hohmann A, Cairns E, Brisco M, Bell DA, Diamond B (1995) Immunoglobulin gene sequence analysis of anti-cardiolipin and anti-cardiolipin idiotype (H3) human monoclonal antibodies. Autoimmunity 22:49–58PubMedCrossRefGoogle Scholar
  31. 31.
    Zangemeister-Wittke U (2005) Antibodies for targeted cancer therapy—technical aspects and clinical perspectives. Pathobiology 72:279–286PubMedCrossRefGoogle Scholar
  32. 32.
    Kipriyanov SM, Le Gall F (2004) Generation and production of engineered antibodies. Mol Biotechnol 26:39–60PubMedCrossRefGoogle Scholar
  33. 33.
    Berger M, Shankar V, Vafai A (2002) Therapeutic applications of monoclonal antibodies. Am J Med Sci 324:14–30PubMedCrossRefGoogle Scholar
  34. 34.
    Lonial S et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30(16):1953–9PubMedCrossRefGoogle Scholar
  35. 35.
    Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC (2011) Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol  10.1111/j.1365-2141.2011.08790.x
  36. 36.
    Reff ME et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445PubMedGoogle Scholar
  37. 37.
    Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I (2000) Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 204:55–63PubMedCrossRefGoogle Scholar
  38. 38.
    Di Gaetano N et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581–1587PubMedGoogle Scholar
  39. 39.
    Uchida J et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659–1669PubMedCrossRefGoogle Scholar
  40. 40.
    Racila E et al (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697–6703PubMedCrossRefGoogle Scholar
  41. 41.
    Cragg MS, Glennie MJ (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738–2743PubMedCrossRefGoogle Scholar
  42. 42.
    Kennedy AD et al (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280–3288PubMedGoogle Scholar
  43. 43.
    Cartron G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758PubMedCrossRefGoogle Scholar
  44. 44.
    Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947PubMedCrossRefGoogle Scholar
  45. 45.
    Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635–2642PubMedCrossRefGoogle Scholar
  46. 46.
    Gordon AN et al (2004) CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94:340–351PubMedCrossRefGoogle Scholar
  47. 47.
    Hilchey SP et al (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 113:3809–3812PubMedCrossRefGoogle Scholar
  48. 48.
    Byrd JC et al (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99:1038–1043PubMedCrossRefGoogle Scholar
  49. 49.
    Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRefGoogle Scholar
  50. 50.
    Forstpointner R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064–3071PubMedCrossRefGoogle Scholar
  51. 51.
    Reid E, Nooka A, Blackmon J, Lechowicz MJ (2012) Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman’s disease. Curr Drug Deliv 9:41–51PubMedCrossRefGoogle Scholar
  52. 52.
    Beers SA et al (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115:5191–5201PubMedCrossRefGoogle Scholar
  53. 53.
    Khan KD et al (2006) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res 12:7046–7053PubMedCrossRefGoogle Scholar
  54. 54.
    Bodogai M et al (2012) Failure of Rituximab in solid tumors is due to its inability to eliminate tumor evoked B regulatory cells. J Immunol 165:115Google Scholar
  55. 55.
    Cheson BD (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28:3525–3530PubMedCrossRefGoogle Scholar
  56. 56.
    Hagenbeek A et al (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111:5486–5495PubMedCrossRefGoogle Scholar
  57. 57.
    Coiffier B et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 111:1094–1100PubMedCrossRefGoogle Scholar
  58. 58.
    Teeling JL et al (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362–371PubMedGoogle Scholar
  59. 59.
    Teeling JL et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793–1800PubMedCrossRefGoogle Scholar
  60. 60.
    Kahl BS, Cheson BD, Friedberg JW (2010) Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol 8:1–16PubMedGoogle Scholar
  61. 61.
    De Mattos-Arruda L, Cortes J (2012) Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist 17(5):631–44PubMedCrossRefGoogle Scholar
  62. 62.
    Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97:453–457PubMedCrossRefGoogle Scholar
  63. 63.
    Moasser MM (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:6577–6592PubMedCrossRefGoogle Scholar
  64. 64.
    Sliwkowski MX (2003) Ready to partner. Nat Struct Biol 10:158–159PubMedCrossRefGoogle Scholar
  65. 65.
    Sierke SL, Cheng K, Kim HH, Koland JG (1997) Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 322(Pt 3):757–763PubMedGoogle Scholar
  66. 66.
    Tzahar E et al (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276–5287PubMedGoogle Scholar
  67. 67.
    Amar S, Roy V, Perez EA (2009) Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 114:413–422PubMedCrossRefGoogle Scholar
  68. 68.
    Perez EA et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373PubMedCrossRefGoogle Scholar
  69. 69.
    Seidman A et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–1221PubMedCrossRefGoogle Scholar
  70. 70.
    Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280PubMedCrossRefGoogle Scholar
  71. 71.
    Perez EA, Spano JP (2011) Current and emerging targeted therapies for metastatic breast cancer. Cancer 118(12):3014–25PubMedCrossRefGoogle Scholar
  72. 72.
    Baselga J et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144PubMedCrossRefGoogle Scholar
  73. 73.
    De Vita F et al (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 16(Suppl 2):S29–S34PubMedCrossRefGoogle Scholar
  74. 74.
    Okines AF, Cunningham D (2010) Trastuzumab in gastric cancer. Eur J Cancer 46:1949–1959PubMedCrossRefGoogle Scholar
  75. 75.
    Hofmann M et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797–805PubMedCrossRefGoogle Scholar
  76. 76.
    Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327PubMedCrossRefGoogle Scholar
  77. 77.
    Demko S, Summers J, Keegan P, Pazdur R (2008) FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 13:167–174PubMedCrossRefGoogle Scholar
  78. 78.
    Hillmen P et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616–5623PubMedCrossRefGoogle Scholar
  79. 79.
    Kennedy GA et al (2003) Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 71:250–256PubMedCrossRefGoogle Scholar
  80. 80.
    Lundin J et al (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101:4267–4272PubMedCrossRefGoogle Scholar
  81. 81.
    de Gramont A et al (2011) From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol 38:521–532PubMedCrossRefGoogle Scholar
  82. 82.
    Klapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25–79PubMedCrossRefGoogle Scholar
  83. 83.
    Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167PubMedCrossRefGoogle Scholar
  84. 84.
    Cohen S, Carpenter G, King L Jr (1980) Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834–4842PubMedGoogle Scholar
  85. 85.
    Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550–6565PubMedCrossRefGoogle Scholar
  86. 86.
    Sato JD et al (1983) Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511–529PubMedGoogle Scholar
  87. 87.
    Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318PubMedGoogle Scholar
  88. 88.
    Wheeler DL et al (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27:3944–3956PubMedCrossRefGoogle Scholar
  89. 89.
    Van Cutsem E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417PubMedCrossRefGoogle Scholar
  90. 90.
    Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671PubMedCrossRefGoogle Scholar
  91. 91.
    Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90:675–684PubMedCrossRefGoogle Scholar
  92. 92.
    Benvenuti S et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648PubMedCrossRefGoogle Scholar
  93. 93.
    Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98–99PubMedCrossRefGoogle Scholar
  94. 94.
    Alberts SR et al (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307:1383–1393PubMedCrossRefGoogle Scholar
  95. 95.
    Weickhardt AJ et al (2012) Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 30:1505–1512PubMedCrossRefGoogle Scholar
  96. 96.
    Bonner JA et al (2009) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRefGoogle Scholar
  97. 97.
    Burtness B et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654PubMedCrossRefGoogle Scholar
  98. 98.
    Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L (2009) Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 9:1421–1428PubMedCrossRefGoogle Scholar
  99. 99.
    Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK (2012) The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 12:517–528PubMedCrossRefGoogle Scholar
  100. 100.
    Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S (2011) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11(Suppl 1):S9–S19PubMedGoogle Scholar
  101. 101.
    Vermorken JB et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171–2177PubMedCrossRefGoogle Scholar
  102. 102.
    Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17:23–28PubMedGoogle Scholar
  103. 103.
    Yang BB et al (2010) Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 49:729–740PubMedCrossRefGoogle Scholar
  104. 104.
    Jonker DJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048PubMedCrossRefGoogle Scholar
  105. 105.
    Van Cutsem E et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664PubMedCrossRefGoogle Scholar
  106. 106.
    Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705PubMedCrossRefGoogle Scholar
  107. 107.
    Paez JG et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  108. 108.
    Lynch TJ et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  109. 109.
    Pao W et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311PubMedCrossRefGoogle Scholar
  110. 110.
    Allegra CJ et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096PubMedCrossRefGoogle Scholar
  111. 111.
    Shigematsu H et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346PubMedCrossRefGoogle Scholar
  112. 112.
    Le Calvez F et al (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65:5076–5083PubMedCrossRefGoogle Scholar
  113. 113.
    Sartore-Bianchi A et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857PubMedCrossRefGoogle Scholar
  114. 114.
    Khambata-Ford S et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237PubMedCrossRefGoogle Scholar
  115. 115.
    Kurai J et al (2007) Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552–1561PubMedCrossRefGoogle Scholar
  116. 116.
    Ciardiello F et al (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784–793PubMedCrossRefGoogle Scholar
  117. 117.
    Bianco R et al (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14:5069–5080PubMedCrossRefGoogle Scholar
  118. 118.
    Sok JC et al (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073PubMedCrossRefGoogle Scholar
  119. 119.
    Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F (2007) Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75:788–799PubMedCrossRefGoogle Scholar
  120. 120.
    Wheeler DL et al (2009) Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8:696–703PubMedCrossRefGoogle Scholar
  121. 121.
    Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445–2459PubMedCrossRefGoogle Scholar
  122. 122.
    Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–1324PubMedCrossRefGoogle Scholar
  123. 123.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRefGoogle Scholar
  124. 124.
    Kowanetz M, Ferrara N (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12:5018–5022PubMedCrossRefGoogle Scholar
  125. 125.
    Goel S et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121PubMedCrossRefGoogle Scholar
  126. 126.
    Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  127. 127.
    Hochster HS et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26:3523–3529PubMedCrossRefGoogle Scholar
  128. 128.
    Saltz LB et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRefGoogle Scholar
  129. 129.
    Giantonio BJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544PubMedCrossRefGoogle Scholar
  130. 130.
    Goldberg RM et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMedCrossRefGoogle Scholar
  131. 131.
    Grothey A et al (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183–189PubMedCrossRefGoogle Scholar
  132. 132.
    Edeline J et al (2012) Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118:147–156PubMedCrossRefGoogle Scholar
  133. 133.
    Krajewski KM et al (2011) Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 59:856–862PubMedCrossRefGoogle Scholar
  134. 134.
    Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47:11–17PubMedCrossRefGoogle Scholar
  135. 135.
    Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  136. 136.
    Reck M et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804–1809PubMedCrossRefGoogle Scholar
  137. 137.
    Besse B et al (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269–278PubMedCrossRefGoogle Scholar
  138. 138.
    Ramalingam SS et al (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26:60–65PubMedCrossRefGoogle Scholar
  139. 139.
    Miller K et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRefGoogle Scholar
  140. 140.
    Miles DW et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239–3247PubMedCrossRefGoogle Scholar
  141. 141.
    Brufsky AM et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286–4293PubMedCrossRefGoogle Scholar
  142. 142.
    Robert NJ et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260PubMedCrossRefGoogle Scholar
  143. 143.
    Cortes J et al (2012) Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 23:1130–1137PubMedCrossRefGoogle Scholar
  144. 144.
    Jayson GC, Hicklin DJ, Ellis LM (2012) Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol 9:297–303PubMedCrossRefGoogle Scholar
  145. 145.
    Burkhardt JK et al (2012) Intra-arterial delivery of bevacizumab after blood–brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 77:130–134PubMedCrossRefGoogle Scholar
  146. 146.
    Friedman HS et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740PubMedCrossRefGoogle Scholar
  147. 147.
    De Fazio S, Russo E, Ammendola M, Donato Di Paola E, De Sarro G (2012) Efficacy and safety of bevacizumab in glioblastomas. Curr Med Chem 19:972–981PubMedCrossRefGoogle Scholar
  148. 148.
    Escudier B et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRefGoogle Scholar
  149. 149.
    Rini BI et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428PubMedCrossRefGoogle Scholar
  150. 150.
    Miljkovic MD, Girotra M, Abraham RR, Erlich RB (2012) Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 57:9–18PubMedCrossRefGoogle Scholar
  151. 151.
    Burger RA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483PubMedCrossRefGoogle Scholar
  152. 152.
    Fogelman D et al (2011) Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 68:1431–1438PubMedCrossRefGoogle Scholar
  153. 153.
    Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299–309PubMedCrossRefGoogle Scholar
  154. 154.
    Batchelor TT et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMedCrossRefGoogle Scholar
  155. 155.
    Yan M, Plowman GD (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clinical Cancer Res 13:7243–7246CrossRefGoogle Scholar
  156. 156.
    Fischer C et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463–475PubMedCrossRefGoogle Scholar
  157. 157.
    D'Amore PA (2007) Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 171:14–18PubMedCrossRefGoogle Scholar
  158. 158.
    Reinmuth N et al (2001) Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15:1239–1241PubMedGoogle Scholar
  159. 159.
    Shaheen RM et al (2001) Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61:1464–1468PubMedGoogle Scholar
  160. 160.
    Pietras K, Pahler J, Bergers G, Hanahan D (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5:e19PubMedCrossRefGoogle Scholar
  161. 161.
    Moreno Garcia V, Basu B, Molife LR, Kaye SB (2012) Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 18(14):3750–61PubMedCrossRefGoogle Scholar
  162. 162.
    Neumann F, Zohren F, Haas R (2009) The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 9:1099–1106PubMedCrossRefGoogle Scholar
  163. 163.
    Podar K et al (2011) The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 155:438–448PubMedCrossRefGoogle Scholar
  164. 164.
    Lewiecki EM, Bilezikian JP (2011) Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin Pharmacol Ther 91:123–133PubMedCrossRefGoogle Scholar
  165. 165.
    Dore RK (2011) The RANKL pathway and denosumab. Rheum Dis Clin North Am 37:433–452, vi–viiPubMedCrossRefGoogle Scholar
  166. 166.
    Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119PubMedCrossRefGoogle Scholar
  167. 167.
    Curiel TJ et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRefGoogle Scholar
  168. 168.
    Ishida T, Ueda R (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139–1146PubMedCrossRefGoogle Scholar
  169. 169.
    Yamamoto K et al (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591–1598PubMedCrossRefGoogle Scholar
  170. 170.
    Antoniu SA (2010) Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther 12:770–779PubMedGoogle Scholar
  171. 171.
    Ishida T et al (2012) Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30:837–842PubMedCrossRefGoogle Scholar
  172. 172.
    Zhang J, Patel L, Pienta KJ (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21:41–48PubMedCrossRefGoogle Scholar
  173. 173.
    Rozel S et al (2009) Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem 107:58–64PubMedCrossRefGoogle Scholar
  174. 174.
    Qian BZ et al (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222–225PubMedCrossRefGoogle Scholar
  175. 175.
    Garber K (2009) First results for agents targeting cancer-related inflammation. J Natl Cancer Inst 101:1110–1112PubMedCrossRefGoogle Scholar
  176. 176.
    Berek JS (2004) Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther 4:1159–1165PubMedCrossRefGoogle Scholar
  177. 177.
    Ehlen TG et al (2005) A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15:1023–1034PubMedCrossRefGoogle Scholar
  178. 178.
    Bayes M, Rabasseda X, Prous JR (2007) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 29:53–71PubMedGoogle Scholar
  179. 179.
    Berek J et al (2009) Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27:418–425PubMedCrossRefGoogle Scholar
  180. 180.
    Teng L, Xie J, Lee RJ (2012) Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv 9(8):901–908PubMedCrossRefGoogle Scholar
  181. 181.
    Jelovac D, Armstrong DK (2012) Role of Farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des 18(25):3812–5PubMedCrossRefGoogle Scholar
  182. 182.
    Pegram MD et al (2009) Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 11:R73PubMedCrossRefGoogle Scholar
  183. 183.
    Beatson RE, Taylor-Papadimitriou J, Burchell JM (2010) MUC1 immunotherapy. Immunotherapy 2:305–327PubMedCrossRefGoogle Scholar
  184. 184.
    Oei AL et al (2008) Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 123:1848–1853PubMedCrossRefGoogle Scholar
  185. 185.
    Ibrahim NK et al (2011) Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 17:6822–6830PubMedCrossRefGoogle Scholar
  186. 186.
    Apostolopoulos V et al (2006) Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 8:R27PubMedCrossRefGoogle Scholar
  187. 187.
    Bell-McGuinn KM et al (2011) A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273–279PubMedCrossRefGoogle Scholar
  188. 188.
    Carter A (2010) Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst 102:675–677PubMedCrossRefGoogle Scholar
  189. 189.
    Almokadem S, Belani CP (2012) Volociximab in cancer. Expert Opin Biol Ther 12:251–257PubMedCrossRefGoogle Scholar
  190. 190.
    Kuwada SK (2007) Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther 9:92–98PubMedGoogle Scholar
  191. 191.
    Tolcher AW et al (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390–1395PubMedCrossRefGoogle Scholar
  192. 192.
    Leong S et al (2009) Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 27:4413–4421PubMedCrossRefGoogle Scholar
  193. 193.
    Younes A et al (2010) A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma. Br J Cancer 103:1783–1787PubMedCrossRefGoogle Scholar
  194. 194.
    Trarbach T et al (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102:506–512PubMedCrossRefGoogle Scholar
  195. 195.
    Hersey P et al (2010) A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or − dacarbazine in patients with stage IV metastatic melanoma. Cancer 116:1526–1534PubMedCrossRefGoogle Scholar
  196. 196.
    Delbaldo C et al (2008) Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 26:35–43PubMedCrossRefGoogle Scholar
  197. 197.
    Chong G et al (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3 H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 17:437–442PubMedCrossRefGoogle Scholar
  198. 198.
    Meyer T et al (2009) A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 15:4484–4492PubMedCrossRefGoogle Scholar
  199. 199.
    Shibata S et al (2009) A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 15:2935–2941PubMedCrossRefGoogle Scholar
  200. 200.
    Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM (2009) CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 15:6052–6061PubMedCrossRefGoogle Scholar
  201. 201.
    Schmidt M et al (2012) Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol 23:2306–13Google Scholar
  202. 202.
    Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10:3937–3942PubMedCrossRefGoogle Scholar
  203. 203.
    Hassan R et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132–6138PubMedCrossRefGoogle Scholar
  204. 204.
    Liu R, Li H, Liu L, Yu J, Ren X (2012) Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 13:123–129PubMedCrossRefGoogle Scholar
  205. 205.
    Scott AM et al (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647PubMedGoogle Scholar
  206. 206.
    Balkwill FR, Mantovani A (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22:33–40PubMedCrossRefGoogle Scholar
  207. 207.
    Lust JA et al (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84:114–122PubMedCrossRefGoogle Scholar
  208. 208.
    Dodson S et al (2010) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279CrossRefGoogle Scholar
  209. 209.
    Maccio A et al (2012) A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124:417–425PubMedCrossRefGoogle Scholar
  210. 210.
    Madeddu C et al (2012) Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +/− megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 31:176–182PubMedCrossRefGoogle Scholar
  211. 211.
    Rech AJ et al (2012) CD25 blockade depletes and selectively reprograms regulatory T-cells and cooperates with immunotherapy in cancer patients. Sci Transl Med 4(134):134ra62PubMedCrossRefGoogle Scholar
  212. 212.
    Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361–371PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Cancer Therapy & Research CenterUniversity of Texas Health Science Center, Adult Cancer Program, STRF MC8252San AntonioUSA

Personalised recommendations